dc.contributor.author | Erdogan, Mehmet | |
dc.contributor.author | Ozbek, Mustafa | |
dc.contributor.author | Akbal, Erdem | |
dc.contributor.author | Ureten, Kemal | |
dc.date.accessioned | 2020-06-25T18:34:24Z | |
dc.date.available | 2020-06-25T18:34:24Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Erdoğan M., Özbek M., Akbal E.,Üreten K. (2019). Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission. Turkish Journal of Medical Sciences, 49(5), 1381 - 1385. | en_US |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issn | 1303-6165 | |
dc.identifier.uri | https://doi.org/10.3906/sag-1812-231 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12587/7899 | |
dc.description | WOS: 000504050500017 | en_US |
dc.description | PubMed: 31549496 | en_US |
dc.description.abstract | Background/aim: Acromegaly is associated with increased morbidity and mortality, mostly due to cardiovascular complications. Plasma thrombin-activatablc fibrinolysis inhibitor (TAFI) antigen levels arc associated with coagulation/fibrinolysis and inflammation. Plasma TAFI may play a role in arterial thrombosis in cardiovascular diseases. In this study, it was aimed to evaluate the thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and homocysteine levels in patients with acromegaly and healthy control subjects. Materials and methods: Plasma TAFI antigen and homocysteine levels in 29 consecutive patients with acromegaly and 26 age-matched healthy control subjects were measured. All patients included in the study were in remission. The TAFIa/ai antigen in the plasma samples was measured using a commercially available ELISA kit. Results: Routine biochemical parameters, fasting blood glucose, prolactin, thyroid stimulating hormone, total-cholesterol, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were similar in the 2 groups (P > 0.05), whereas the plasma TAFI antigen levels were significantly elevated in the acromegalic patients (154.7 +/- 94.0%) when compared with the control subjects (107.2 +/- 61.6%) (P = 0.033). No significant correlation was identified by Pearson's correlation test between the plasma TAFI antigen and homocysteine levels (r = 0.320, P = 0.250). Conclusion: A significant alteration in the plasma TAFI antigen levels was detected in acromegaly. Increased plasma TAFI antigen levels might aggravate prothrombotic and thrombotic events in patients with acromegaly. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Tubitak Scientific & Technical Research Council Turkey | en_US |
dc.relation.isversionof | 10.3906/sag-1812-231 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | TAFI antigen | en_US |
dc.subject | acromegaly | en_US |
dc.subject | cardiovascular disease | en_US |
dc.title | Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission | en_US |
dc.type | article | en_US |
dc.contributor.department | Kırıkkale Üniversitesi | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 1381 | en_US |
dc.identifier.endpage | 1385 | en_US |
dc.relation.journal | Turkish Journal Of Medical Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |